FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells

BACKGROUND: OX40 (CD134) is a costimulatory molecule of the tumor necrosis factor receptor superfamily that is currently being investigated as a target for cancer immunotherapy. However, despite promising results in murine tumor models, the clinical efficacy of agonistic αOX40 antibodies in the trea...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Campos Carrascosa, Lucia, van Beek, Adriaan A, de Ruiter, Valeska, Doukas, Michail, Wei, Jie, Fisher, Timothy S, Ching, Keith, Yang, Wenjing, van Loon, Karlijn, Boor, Patrick P C, Rakké, Yannick S, Noordam, Lisanne, Doornebosch, Pascal, Grünhagen, Dirk, Verhoef, Kees, Polak, Wojciech G, IJzermans, Jan N M, Ni, Irene, Yeung, Yik Andy, Salek-Ardakani, Shahram, Sprengers, Dave, Kwekkeboom, Jaap
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2020
Pynciau:
Clinical/Translational Cancer Immunotherapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7478034/
https://ncbi.nlm.nih.gov/pubmed/32900860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000816
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg